Cue Biopharma Earnings Call Transcripts
Fiscal Year 2026
-
Precision immunoengineering drives a portfolio targeting allergic and autoimmune diseases, with CUE-221 and CUE-401 advancing through key clinical milestones. CUE-221 shows rapid, durable IgE suppression and is benchmarked against omalizumab, while CUE-401 targets regulatory T cell expansion for autoimmune therapy.
-
Stockholders approved the issuance of shares related to a licensing transaction, the 2026 Stock Incentive Plan, and the potential adjournment of the meeting if needed. Voting procedures and governance protocols were followed, with final results to be filed on Form 8-K.
-
Shareholders approved all proposals, including director elections, auditor ratification, executive compensation, and a reverse stock split. No questions were submitted, and the meeting was conducted virtually with a confirmed quorum.
-
CUE-401, a bifunctional molecule targeting TGF-β and IL-2, is advancing to phase I trials following strong preclinical efficacy and safety data. Strategic partnerships have generated significant non-dilutive funding, de-risking the pipeline and supporting ongoing R&D.
Fiscal Year 2025
-
Phase III trials for VK2735 in obesity are progressing well, with strong efficacy and tolerability seen in phase II oral studies. The company is expanding its team, advancing an amylin analog program, and focusing on both subcutaneous and oral maintenance regimens to address long-term obesity management.
-
CUE-401, a novel bispecific biologic, demonstrated robust induction and expansion of regulatory T cells, durable suppression of autoimmunity, and favorable tolerability in preclinical models. The platform’s breadth enables targeting multiple autoimmune and cancer indications, with strategic partnerships and IND-enabling studies advancing.
-
Announced a strategic collaboration with Boehringer Ingelheim for Cue-501, including $12 million upfront, up to $345 million in milestones, and royalties. The partnership accelerates development of a first-in-class B cell depletion therapy and provides non-dilutive funding.
Fiscal Year 2024
-
The Immuno-STAT platform enables precise immune modulation for cancer and autoimmune diseases, with CUE-101 showing strong survival benefits in head and neck cancer and promising results in low PD-L1 patients. Autoimmune programs, including CUE-401 and CUE-501, are advancing with strategic partnerships and a solid financial runway.
-
The platform enables modular targeting of T cells for cancer and autoimmune diseases, with CUE-101 and CUE-102 showing strong survival and response rates in head and neck and other cancers. Autoimmune programs, partnered with Ono, are advancing with promising preclinical data and a focus on strategic, value-adding partnerships.
-
Corporate restructuring prioritized autoimmune programs and extended cash runway to mid-2025. CUE-101 demonstrated strong survival benefits in head and neck cancer, while CUE-401 and CUE-501 advanced with promising preclinical data and ongoing partnership discussions.
-
The platform enables selective immune modulation for oncology and autoimmune diseases, with clinical data showing strong efficacy and safety in head and neck and other cancers. Regulatory alignment accelerates development, while preclinical autoimmune programs offer novel approaches for immune balance and B cell depletion.